Bpi Labs Company Profile
What is the competitive landscape for BPI LABS
BPI LABS has ten approved drugs.
There are two tentative approvals on BPI LABS drugs.
Summary for Bpi Labs
| US Patents: | 0 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 10 |
| PTAB Cases with Bpi Labs as petitioner: | See PTAB cases with Bpi Labs as petitioner |
Drugs and US Patents for Bpi Labs
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bpi Labs | FLUORESCEIN SODIUM | fluorescein sodium | INJECTABLE;INTRAVENOUS | 220046-001 | Apr 30, 2026 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bpi Labs | NALOXONE HYDROCHLORIDE | naloxone hydrochloride | INJECTABLE;INJECTION | 216977-001 | Oct 6, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bpi Labs | ABLYSINOL | dehydrated alcohol | SOLUTION;INTRA-ARTERIAL | 207987-001 | Jun 21, 2018 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Bpi Labs | EPINEPHRINE | epinephrine | SOLUTION;INTRAVENOUS | 205029-003 | May 12, 2023 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Bpi Labs | TESTOSTERONE CYPIONATE | testosterone cypionate | INJECTABLE;INJECTION | 219478-001 | Sep 3, 2026 | AO | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bpi Labs | ABLYSINOL | dehydrated alcohol | SOLUTION;INTRA-ARTERIAL | 207987-002 | Jun 21, 2018 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bpi Labs | ZOLEDRONIC ACID | zoledronic acid | INJECTABLE;INTRAVENOUS | 207341-001 | Dec 29, 2017 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

